ERK-Stabilized Suicide Gene Therapy for Glioblastoma Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for glioblastoma multiforme, face challenges due to resistance mechanisms that maintain extracellular regulated kinase (ERK) signaling, limiting the effectiveness of existing pharmacological inhibitors and surgical resection of diffusely spread tumor cells.
Innovation Solution
A vector comprising a nucleic acid sequence encoding a promoter operably linked to a therapeutic polypeptide, such as Herpes simplex virus thymidine kinase (HSVtk) or yeast cytosine deaminase, fused with a peptide domain stabilized by ERK phosphorylation, is used to convert a prodrug into a toxic product, specifically targeting ERK-dependent cancer cells through ERK-stabilized suicide gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological inhibitors are used to target Ras/Raf/MEK/ERK pathway nodes, then cancer cell signaling is inhibited, but cancer cells develop resistance through maintenance of ERK signaling
Solution Approach 1:
The patent uses a suicide gene (HSVtk or yeast cytosine deaminase) as an intermediary agent that converts a prodrug into a toxic product. This mediator approach bypasses the traditional pharmacological inhibition pathway that cancer cells can resist, creating a new mechanism of action that directly kills ERK-dependent cancer cells through prodrug activation rather than signaling pathway inhibition.
Solution Approach 2:
The patent changes the fundamental parameter of treatment mechanism from pharmacological inhibition to enzymatic prodrug conversion. By fusing the suicide gene to an ERK-dependent peptide domain, the system activates the toxic product only in cells with aberrant ERK activity, fundamentally altering how cancer cells are targeted and overcoming resistance through a different biochemical pathway.
2Reliability
If high prodrug doses are administered to overcome resistance, then cancer cell killing is enhanced, but specificity to cancer cells is reduced and normal cells are affected
Solution Approach 1:
The patent applies local quality by making the prodrug activation specific to cancer cells with aberrant ERK activity. The ERK-dependent peptide domain acts as a localized switch that only allows toxic product formation in the specific cell population that expresses the fusion protein, ensuring that even at high prodrug doses, only the target cancer cells are affected while normal cells remain protected.
Solution Approach 2:
The system incorporates feedback through the ERK-dependent peptide domain that senses aberrant ERK activity levels. This feedback mechanism ensures that the suicide gene is only expressed and activated in cells with the specific molecular signature of cancer (aberrant ERK signaling), creating a self-regulating system that maintains specificity regardless of prodrug dose.
3Quantity of substance
If surgical resection is used to remove tumor cells, then visible tumor mass is reduced, but diffusely spread tumor cells cannot be completely removed
Solution Approach 1:
The patent creates a universal treatment approach that addresses both macroscopic tumor mass and microscopic diffusely spread cells through a single prodrug administration. The ERK-dependent fusion protein expression and subsequent prodrug activation occur in all cancer cells regardless of their spatial distribution, providing multi-functional coverage that surgery cannot achieve.
Solution Approach 2:
The patent employs preliminary action by genetically modifying cancer cells to express the ERK-dependent suicide gene before prodrug administration. This preliminary genetic preparation ensures that when the prodrug is administered, all cancer cells (including diffusely spread ones) are pre-equipped to convert the prodrug into toxic product, eliminating the need for physical removal and ensuring complete eradication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach selectively kills cancer cells with aberrant ERK activity, overcoming resistance mechanisms and reducing the need for high prodrug doses, while maintaining specificity to cancer cells, potentially enhancing treatment outcomes for glioblastoma and other ERK-dependent cancers.
Implementation Method 1
a therapeutic polypeptide, such as Herpes simplex virus thymidine kinase (HSVtk) or yeast cytosine deaminase, fused with a peptide domain stabilized by ERK phosphorylation, is used to convert a prodrug into a toxic product
Implementation Method 2
a peptide domain stabilized by ERK phosphorylation
Data Source
AI summary
Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some aspects, the method comprises administering to the subject a vector comprising a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target tissue. The kinase activity can be elevated extracellular regulated kinase (ERK) activity.